Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update

Arcutis Biotherapeutics reported third-quarter 2026 net product revenue of $143.9 million, up 45% year over year and 11% from the prior quarter, and raised its full-year sales guidance to $535 million–$545 million. The company generated $18.9 million in net cash from operating activities. Arcutis launched an inflammatory skin-condition awareness campaign featuring Simone Biles and said it remains on track to report topline results from its Phase 2 ZORYVE foam trial for vitiligo in the fourth quarter of 2026.